MARLBOROUGH, Mass.--(BUSINESS WIRE)--Xcellerex, Inc. announced today that Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) is acquiring a FlexFactory™ bioproduction line and multiple XDR single-use bioreactors, to rapidly expand the capacity and flexibility of its manufacturing capabilities. Crucell is the latest company to purchase a FlexFactory, Xcellerex’s innovative, modular turnkey manufacturing platform. The project will deliver new, validated clinical manufacturing capacity at Crucell’s operations in Leiden, The Netherlands during the first quarter of 2010, enabling Crucell to commence production years faster than with conventional technologies. Financial terms were not disclosed.
